Xueba’s medical black technology system

Chapter 220: Listing in China will not be considered for the time being

"Dad, don't worry, I've heard the news. A drug is coming out recently. It's a targeted drug specifically for the treatment of pancreatic cancer. It's from abroad and it's very effective."

"Don't worry. Don't worry about money. Will your son still have no money?"

"Really, Dad, cancer is not scary now. I have asked the doctor. As long as you take medicine on time, there is still a chance."

"Okay, Dad, I'll hang up first."

After ending the call with his father, Guo Gang looked tired and rubbed his swollen eyebrows, and then breathed a long sigh of relief.

Just this year, Guo Gang suddenly received the news that his father was diagnosed with pancreatic cancer.

Guo Gang was so worried that after hurriedly asking for leave from his work unit, Guo Gang rushed back to his hometown overnight.

When Guo Gang saw his father lying on the hospital bed, he really didn't dare to connect the person in front of him with his father.

In Guo Gang's impression, although his father is over 60 years old, he has always been in good health because he exercised regularly when he was young. He has a loud voice and walks with wind.

But now, the father lying on the bed can be said to be skinny and sallow, as if he is dying.

The whole person's energy seemed to have been drained.

Guo Gang knew that cancer can sometimes make people miserable, but he didn't dare to think about what kind of pain it would take to torture a person to the point of not being human.

After that, Guo Gang also searched for doctors and medicines everywhere, joined various patient groups, and looked for treatment plans that had been used by patients and were successful.

But the problem was that his father was already in stage 4 at that time, which was in the late stage.

What about paclitaxel + gemcitabine, or nanoliposomal irinotecan + fluorouracil and other regimens?

In short, all available chemotherapy drugs have been used, but their effect is almost negligible.

Not to mention immunotherapy, many patients have already tried immunotherapy drugs similar to PD-1, which do not have much effect on patients with advanced pancreatic cancer.

This made Guo Gang feel a little desperate for a while.

But fortunately, there is no unparalleled road.

Just yesterday, he suddenly saw news that the foreign company Pfizer had developed a targeted drug for pancreatic cancer. The clinical effect was very good, and it would not be long before the drug would be available on the market.

This gave Guo Gang a glimmer of hope.

Guo Gang picked up his phone and opened the patient group. There were still many people chatting in the patient group at this moment.

"This drug may not completely cure pancreatic cancer, but it can at least give everyone a few more years of life."

"This is enough, at least it's better than nothing."

With the advent of new drugs for pancreatic cancer, people in the patient community are beginning to become optimistic.

"Haha, I just don't know when this drug from Pfizer will be available in China." Some people are even eager to try it.

When he saw this, Guo Gang couldn't help but raise the corners of his mouth slightly, just when he was about to express his feelings in the patient group.

With a ding-dong sound, a message popped up from the patient group. When he saw the message, Guo Gang's fingers suddenly froze.

"It is estimated that this drug will not be available in China for a while." The message was sent by another patient in the group.

This sentence made the patients in the group stunned for a moment.

"What did you say? You must have been asleep, haha."

"How do you know that it won't be launched in China for a while? Have you heard false news?" But the patient didn't refute anything. He just forwarded a picture to the patient group. It was a piece of news. screenshot.

The news about the new drug was yesterday, but the news was released today.

The moment he saw the news title in the screenshot, Guo Gang's hands and feet instantly became cold. Guo Gang felt as if he had been forced into the bottomless cold ice water. Stifling cold.

"The person in charge of Pfizer announced that targeted treatment drugs for pancreatic cancer will not be considered for sale in China for the time being. "--New York Times.

A basin of ice water was poured on the hot coals, giving Guo Gang a chill!
"After the Pin1 gene was knocked out in the mice in the experimental group, the expression of the tumor suppressor gene p35 in the mice was down-regulated."

In the study room, Lu Liang looked at the data on his computer screen and analyzed the final results group by group.

Yesterday, he had tested all the samples, and all that was left was data analysis.

Looking at the changes in the expression of the tumor suppressor gene p35 in the two groups of mice, Lu Liang did not have much surprise on his face.

Peptidyl prolyl isomerase Pin1 is inherently closely related to the tumor suppressor gene p35.

After Pin1 deletion in mice, it is normal for the expression of the tumor suppressor gene p35 to decrease.

However, after knocking out Pin1, the proliferation of CAF cells in mice will also be inhibited.

This discovery made Lu Liang frown.

The so-called CAF cells are a type of tumor-related fibroblasts that are highly plastic.

A large number of studies have shown that CAF cells are closely related to tumor growth.

On the one hand, CAF cells can promote the invasion and metastasis of tumor cells, support angiogenesis and inhibit adaptive immune responses to invade tumors and promote tumor occurrence.

On the other hand, CAF cells secrete some cytokines, such as IL6, IL11 and leukemia inhibitory factor.

These cytokines promote the growth of tumor cells.

In addition, CAF cells also inhibit the adaptive immune response and inhibit the function of T cells.

It can be said that with the massive proliferation of CAF cells, these cells will create a microenvironment conducive to tumor growth.

In mice in which Pin1 has been knocked out, the proliferation of CAF cells is inhibited.

Without the matrix proteins provided by CAF cells, this microenvironment conducive to tumor growth will be destroyed.

Therefore, by inhibiting Pin1 in mice, theoretically, tumor growth can be curbed.

However, whether Pin1 can become a target of pancreatic cancer and achieve the purpose of treating pancreatic cancer by inhibiting Pin1.

Based on the current test alone, it is not possible to draw a conclusion yet. It is estimated that another batch of tests will be needed, Lu Liangliang thought.

Just as Lu Liang was thinking about how to design the next experiment, the mobile phone placed on the table suddenly vibrated, and Lu Liang subconsciously glanced at the screen of the mobile phone.

That's a news push message.

Lu Liang originally didn't care too much.

Just when he was about to retract his gaze, Lu Liang's eyes suddenly froze due to the news headlines he accidentally caught.

"The person in charge of Pfizer announced that targeted treatment drugs for pancreatic cancer will not be considered for sale in China for the time being. 》——Reprinted

At this moment, Lu Liang frowned and couldn't help but narrow his eyes slightly.

(End of this chapter)